Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE.
Head-to-head clinical analysis: CENTRAX versus CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE.
CENTRAX vs CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Chlordiazepoxide is a benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion influx and causing CNS depression. Clidinium bromide is an anticholinergic that blocks muscarinic acetylcholine receptors, reducing GI motility and secretions.
10-30 mg orally, 3-4 times daily.
Each tablet contains chlordiazepoxide HCl 5 mg and clidinium bromide 2.5 mg. Typical adult dose: 1-2 tablets orally 3-4 times daily before meals and at bedtime. Max 8 tablets daily.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Chlordiazepoxide has a terminal elimination half-life of 5-30 hours (mean ~24 hours) in adults; its active metabolite desmethylchlordiazepoxide has a half-life of 10-30 hours. Accumulation occurs with repeated dosing. In elderly or hepatic impairment, half-life may be prolonged significantly. Clidinium has a half-life of 10-12 hours.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Chlordiazepoxide is extensively metabolized in the liver to active metabolites (e.g., desmethylchlordiazepoxide, demoxepam). Renal excretion accounts for approximately 20% of unchanged drug; the remainder is excreted as metabolites in urine (80-90%) and feces (10-20%). Clidinium is excreted primarily unchanged in urine (75%) and feces (25%).
Category C
Category D/X
Benzodiazepine
Benzodiazepine